<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260113</url>
  </required_header>
  <id_info>
    <org_study_id>CSSG-06</org_study_id>
    <nct_id>NCT04260113</nct_id>
  </id_info>
  <brief_title>Apatinib for Inoperable Advanced Chondrosarcoma</brief_title>
  <acronym>AIAC</acronym>
  <official_title>The Effectivity and Toxicity of Apatinib for Unresectable Advanced Chondrosarcoma: a Multicentric Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising&#xD;
      effects on prolonging progression-free survival (PFS) for advanced chondrosarcoma after&#xD;
      failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which&#xD;
      specifically inhibits VEGFR-2. This study summarizes the experience of two Peking University&#xD;
      affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated&#xD;
      chondrosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>6 months</time_frame>
    <description>from initial treatment to date of recorded progression or death or last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>from initial treatment to death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>CR+PR according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate</measure>
    <time_frame>6 months</time_frame>
    <description>CR+PR+SD according to RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Efficacy</condition>
  <condition>Toxicity, Drug</condition>
  <arm_group>
    <arm_group_label>Apatinib Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>Apatinib orally 500mg once daily half an hour after meal</description>
    <arm_group_label>Apatinib Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) histologically confirmed high-grade sarcoma;&#xD;
&#xD;
          -  2) initial treatment in the orthopedic oncology departments of the two affiliated&#xD;
             hospitals of Peking University;&#xD;
&#xD;
          -  3) tumors not amenable to curative treatment or inclusion in clinical trials;&#xD;
&#xD;
          -  4) unresectable local advanced lesions or multiple metastatic lesions that could not&#xD;
             be cured by local therapy;&#xD;
&#xD;
          -  5) measurable lesions according to Response Evaluation Criteria for Solid Tumors&#xD;
             (RECIST1.1) ;&#xD;
&#xD;
          -  6) Eastern Cooperative Oncology Group performance status 0 or 1;&#xD;
&#xD;
          -  7) acceptable hematologic, hepatic, and renal function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  had central nervous system metastasis;&#xD;
&#xD;
          -  had other kinds of malignant tumors at the same time; had cardiac insufficiency or&#xD;
             arrhythmia;&#xD;
&#xD;
          -  had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine&#xD;
             protein â‰¥ ++ and so on;&#xD;
&#xD;
          -  had pleural or peritoneal effusion that needs to be handled by surgical treatment;&#xD;
&#xD;
          -  combined with other infections or wounds;&#xD;
&#xD;
          -  pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Musculoskeletal Tumor Center of Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Univresity Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100144</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xie L, Guo W, Wang Y, Yan T, Ji T, Xu J. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China. BMC Cancer. 2018 Apr 6;18(1):396. doi: 10.1186/s12885-018-4303-z.</citation>
    <PMID>29625604</PMID>
  </reference>
  <reference>
    <citation>Xie L, Xu J, Sun X, Tang X, Yan T, Yang R, Guo W. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. Oncologist. 2019 Jul;24(7):e542-e550. doi: 10.1634/theoncologist.2018-0542. Epub 2018 Dec 17.</citation>
    <PMID>30559126</PMID>
  </reference>
  <results_reference>
    <citation>Xie L, Xu J, Sun X, Liu K, Li X, He F, Liu X, Gu J, Lv Z, Yang R, Tang X, Yan T, Li D, Yang Y, Dong S, Sun K, Shen D, Guo W. Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study. Cancer Manag Res. 2020 May 15;12:3513-3525. doi: 10.2147/CMAR.S253201. eCollection 2020.</citation>
    <PMID>32547189</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>January 2, 2021</last_update_submitted>
  <last_update_submitted_qc>January 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chondrosarcoma</keyword>
  <keyword>apatinib</keyword>
  <keyword>inoperable</keyword>
  <keyword>toxicity</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

